New drug combo tested against standard therapy in Hard-to-Treat myeloma
NCT ID NCT05028348
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 3 trial tests whether a combination of selinexor, pomalidomide, and dexamethasone works better than elotuzumab, pomalidomide, and dexamethasone for people with multiple myeloma that has come back or stopped responding to treatment. About 117 participants who have already tried 1 to 4 prior therapies will be randomly assigned to one of the two drug regimens. The main goal is to see which combination delays cancer progression longer and improves quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Selinexor (oral drug) combined with pomalidomide and dexamethasone
What this could lead to
If successful, this could offer a new treatment option for patients with multiple myeloma that has returned or not responded to prior therapies.
What could go wrong
This is an early-stage comparison in a small group (117 people). The new combination may not prove better or could have more side effects than the standard regimen.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alexandra General Hospital -Department of Clinical Therapeutics N.K. Univ. of Athens
Athens, Greece
-
CHRU Hôtel Dieu
Nantes, France
-
CHU Hôpital Saint Antoine
Paris, France
-
Clínica Universidad de Navarra (CUN)
Pamplona, Spain
-
Complejo Hospitalario Universitario de Santiago (CHUS)
Santiago de Compostela, Spain
-
H. General Universitario Morales Meseguer
Murcia, Spain
-
H. Universitario Marqués de Valdecilla
Santander, Spain
-
H.U. La Fe
Valencia, Spain
-
Hospital Clinic I Provincial de Barcelona
Barcelona, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, Spain
-
Hospital Universitario 12 de Octubre
Madrid, Spain
-
Hospital Universitario de Salamanca
Salamanca, Spain
-
Hospital de Cabueñes
Gijón, Spain
-
Institut Catala D Oncolocia Hospitalet - Hospital Duran i Reynals
Barcelona, Spain
-
Institut Català D'Oncologia - Hospital Dr. Josep Trueta
Girona, Spain
-
Klinikum Chemnitz
Chemnitz, Germany
-
La Pitié
Paris, France
-
Marien Hospital Dusseldorf
Düsseldorf, Germany
-
University Medicine Greifswald, Medical Clinic and Polyclinic for Internal Medicine
Greifswald, Germany
-
Universitätsklinikum Hamburg - Eppendorf
Hamburg, Germany